Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy

Grønberg, Bjørn Henning; Sundstrøm, Stein; Kaasa, Stein; Bremnes, Roy M.; Fløtten, Øystein; Amundsen, Tore; Hjelde, Harald; Plessen, Christian von; Jordhøy, Marit S.

doi:10.1016/j.ejca.2010.04.009

Cited by 105 publications

(100 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adjuvant chemotherapy should be considered in patients with pathologic stage IB NSCLC, but it has not been used as a routine treatment in pathologic stage IA patients (24). From the treatment per se, upstaging VPI (+) patients for additional cytotoxic therapy (chemotherapy or radiation therapy) because of higher stage may expose them to unnecessary side effects from therapy that may not provide benefit (25). Therefore, a financial and hazard analysis may be conducted to compare those receiving adjuvant therapy with those not receiving the therapy.…”

Section: Discussionmentioning

confidence: 99%

Visceral pleural invasion in lung adenocarcinoma ≤3 cm with ground-glass opacity: a clinical, pathological and radiological study

Zhao¹,

Xie²,

Zhang³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Visceral pleural invasion (VPI) had been demonstrated as an aggressive sign in non-small cell lung cancers (NSCLC). However, its incidence and clinical relevance in early lung cancer showing ground glass nodules (GGNs) has not been clarified. Results: Out of 156 enrolled patients, 38 had pathologically confirmed VPI. The incidence of VPI was 41.5% (27/65) if the tumor diameter was larger than 2.0 cm and 14.3% (13/91) if diameter was smaller than 2.0 cm (P<0.001). Further, the incidence was 17.4% (12/69) in pure GGNs and 32.2% (28/87) in part-solid GGNs (P=0.040). The tumor size and the nodule nodule-pleural relationship were significant predictors of positive VPI. In cases with pleural indentation, attachment, and closeness, the incidence was 38.1%, 25.5%, and 5.3%, respectively (P=0.001). All cases were PL0 and PL1, with no PL2 cases observed.Conclusions: Although VPI was visible in both pure/mix GGNs, it was more common in larger (>2 cm) GGNs. The radiographic findings of nodule abutment or a pleural tag did not reliably predict or exclude VPI. In patients with GGNs, a low rate of PL2 invasion may be observed.

show abstract

Section: Discussionmentioning

confidence: 99%

Visceral pleural invasion in lung adenocarcinoma ≤3 cm with ground-glass opacity: a clinical, pathological and radiological study

Zhao¹,

Xie²,

Zhang³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…Patients with lung cancer receiving radiotherapy commonly experience toxicities several months after treatment, 63 are increasingly receiving combined modality treatments, 64 and often have several other comorbidities. 65,66 Widening the scope of the system to allow for inclusion of additional time points in the lung cancer treatment continuum, measurement of toxicities associated with combined cancer treatments, recognition and distinction of symptoms relating to comorbidities, and evaluation of the wider supportive care needs of patients with lung cancer could render this system more appealing to health professionals in busy clinical settings. In conjunction with the aforementioned developments, reducing the time that clinicians will be required to spend on using the system possibly through use of adequately sized smartphones that could act as both pagers and computer terminals to allow Web access, as well as standardizing the protocols for clinician intervention following an alert, could further enhance the system's clinical utility.…”

Section: Secondary Aim: Change In Patient Outcomesmentioning

confidence: 99%

Development of a Novel Remote Patient Monitoring System

et al. 2015

View full text Add to dashboard Cite

“…Chemotherapy is the preferred treatment method for NSCLC, and gemcitabine plus platinum (GP) is the most common drug combination (1). GP significantly reduces the mortality of NSCLC patients (3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Transcutaneous electrical acupoint stimulation (TEAS) ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients

Hou¹,

Gu²,

Gao³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Background:To investigate the effect of percutaneous electrical stimulation on chemotherapy-induced bone marrow suppression in patients with lung cancer.Methods: From December 2014 to August 2015, one hundred ninety-one non-small cell lung cancer patients with chemotherapy naive were randomly divided into control group, medication group, and transcutaneous electrical acupoint stimulation (TEAS) group. Patients with the control group received routine nursing care, the medication group was treated by oral administration of prophylactic agents, and TEAS group received electrical stimulation of acupoints including Dazhui (DU14), Geshu (BL17), Zusanli (ST36), Sanyinjiao (SP6), and Hegu (LI4). The primary end point was the blood routine indexes and secondary end point was the degree of comfort. Results:The white blood cell in the TEAS group was significantly higher than the control group on day 8 and day 14 (P<0.05). The platelet count in the TEAS group was significantly higher than control group on day 5, day 8 and day 11 (P<0.05). The comfort score in the TEAS group was significantly higher than control group on day 8 (P<0.05).Conclusions: Percutaneous electrical stimulation of acupoints could prevent chemotherapy-induced bone marrow suppression in lung cancer patients and ensure a smooth continuation of chemotherapy.

show abstract

Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy

Cited by 105 publications

References 27 publications

Visceral pleural invasion in lung adenocarcinoma ≤3 cm with ground-glass opacity: a clinical, pathological and radiological study

Visceral pleural invasion in lung adenocarcinoma ≤3 cm with ground-glass opacity: a clinical, pathological and radiological study

Development of a Novel Remote Patient Monitoring System

Transcutaneous electrical acupoint stimulation (TEAS) ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients

Contact Info

Product

Resources

About